Welcome to our dedicated page for Solventum Corporation SEC filings (Ticker: SOLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Solventum Corporation (NYSE: SOLV) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents help investors, analysts and other stakeholders understand Solventum’s financial performance, portfolio actions, capital structure and governance as it operates in the medical instruments and supplies sector.
Solventum uses current reports on Form 8-K to disclose a variety of material events. Examples include 8-K filings reporting quarterly financial results, such as third-quarter 2025 earnings, which incorporate press releases detailing segment performance, non-GAAP measures and updated guidance. Other 8-K filings describe material definitive agreements and their completion, such as the transaction agreement and subsequent closing of the sale of certain assets and liabilities related to Solventum’s purification and filtration business to Thermo Fisher Scientific Inc.
Additional 8-K filings cover capital markets and balance sheet activities, including the commencement, upsizing and pricing of cash tender offers for specified series of senior notes, and an underwriting agreement relating to the sale of shares by a selling shareholder. Governance and leadership changes, such as the appointment of a Chief Commercial Officer and the departure of a segment leader, are also reported on Form 8-K, along with information about related compensation and severance arrangements.
On Stock Titan, users can review these filings alongside AI-powered summaries that explain key points in clear language. This includes highlighting where Solventum discusses its “Transform for the Future” initiative, outlines risk factors, or provides pro forma financial information related to divestitures. The filings page is also a resource for tracking Solventum’s capital allocation strategy, including debt reduction, note tender offers and the authorization of a share repurchase program, as disclosed in its official documents.
Solventum Corp director Wendell Amy McBride bought 1,475 shares of Common Stock in an open-market purchase. The transaction took place on 2026-03-10 at an average price of $68.03 per share. Following this transaction, her direct holdings increased to 5,039 shares of Solventum common stock.
Solventum Corp Chief Information Officer Amy Landucci reported equity compensation activity involving restricted stock units and common shares. On March 5, 2026, she was granted 12,716 Restricted Stock Units (RSUs), each representing a right to receive one share of Class A common stock upon settlement, vesting in three equal annual installments.
On March 6, 2026, 3,795 RSUs were converted into 3,795 shares of common stock, and 1,731 common shares at $69.41 per share were disposed of to cover tax obligations, described as a tax-withholding disposition. After these transactions, her directly held common stock position was 37,483 shares, with 7,593 RSUs remaining from the earlier award.
Solventum Corp Chief Supply Chain Officer Paul S. Harrington reported equity compensation activity and related tax withholding. On March 5, 2026, he was granted 10,950 Restricted Stock Units (RSUs), each representing a right to receive one share of Class A common stock. These RSUs vest in three equal annual tranches on the first, second and third anniversaries of the grant date, subject to continued service. On March 6, 2026, 3,300 RSUs were exercised for 3,300 shares of common stock at a stated price of $0.00, and 1,073 shares of common stock were disposed of at $69.41 per share to cover tax obligations, leaving 18,170 common shares held directly.
Solventum Corp Chief Financial Officer Wayde D. McMillan reported several equity-related transactions. On March 5, 2026, he acquired 35,321 Restricted Stock Units (RSUs) as a grant, each representing a right to receive 1 share of Class A Common Stock. These RSUs vest in three equal annual tranches on the first, second and third anniversaries of the grant date, subject to continued service.
On March 6, 2026, he exercised 8,802 RSUs, converting them into 8,802 shares of Common Stock at a stated price of $0.00 per share. The filing also shows a disposition of 2,786 shares of Common Stock at $69.41 per share in a tax-withholding transaction to satisfy obligations arising from the equity award. After these transactions, his directly held Common Stock position was 43,538 shares, and his directly held RSUs totaled 35,321 units.
Solventum Corp Chief Human Resources Officer Tammy L. Gomez reported multiple equity compensation transactions. On March 5, 2026, she received a grant of 12,716 Restricted Stock Units (RSUs), each representing one share of Class A Common Stock. These RSUs vest in three equal annual installments on the first, second, and third anniversaries of the grant date, subject to continued service.
On March 6, 2026, 3,300 RSUs were exercised and converted into 3,300 shares of Common Stock at no cost, increasing her directly held Common Stock before withholding. To cover tax obligations, 895 Common shares were withheld at $69.41 per share, leaving her with 11,070 shares of Common Stock held directly after these transactions, and 6,603 RSUs remaining from earlier awards plus the new 12,716‑unit grant.
Solventum Corp Chief Executive Officer Bryan C. Hanson reported multiple equity transactions. On March 5, 2026, he acquired 105,963 Restricted Stock Units (RSUs), each representing a contingent right to one share of Class A common stock.
On March 6, 2026, he exercised RSUs covering 31,907 RSUs, receiving 31,907 shares of common stock, and then disposed of 10,395 shares of common stock at $69.41 per share to cover tax withholding. After these transactions, he directly held 123,910 shares of common stock and 105,963 RSUs. The new RSU grant vests in three equal annual tranches, subject to continued service.
Knight Heather reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp reported that Chief Commercial Officer Heather Knight received a grant of 31,789 Restricted Stock Units (RSUs) on March 5, 2026. Each RSU represents a contingent right to receive one share of Solventum’s Class A common stock upon settlement.
The RSUs vest in three equal tranches, with one-third vesting on each of the first, second, and third anniversaries of the grant date, conditioned on Ms. Knight’s continued service through each vesting date. Following this grant, she directly holds 31,789 RSUs.
Solventum Corp’s Chief Legal Affairs Officer, Marcela A. Kirberger, reported several equity-related transactions in company stock. She received a grant of 14,835 Restricted Stock Units (RSUs), each representing one share of Class A Common Stock upon settlement, vesting in three equal annual installments.
On a separate date, she exercised 4,180 RSUs, converting them into the same number of Common Stock shares at a stated price of $0.00 per share, and 1,232 Common Stock shares were disposed of at $69.41 per share to cover tax obligations. Following these transactions, she directly held 11,004 Common Stock shares and 8,363 RSUs.
Solventum Corporation filed its Annual Report on Form 10-K describing its global healthcare operations, spin-off risks and capital structure.
The company reports an aggregate market value of common stock held by non‑affiliates of about $13.1 billion as of its most recent second fiscal quarter and 173,493,005 shares outstanding as of February 18, 2026. Its 2025 sales were led by MedSurg at 57.9%, with Dental Solutions at 16.2% and Health Information Systems at 16.3%.
Solventum highlights its separation from 3M, noting potential challenges in systems, capital access and the loss of 3M scale benefits. As of December 31, 2025, it carried approximately $5 billion of outstanding debt. The report also notes the 2025 acquisition of Acera Surgical and the sale of its Purification and Filtration business to Thermo Fischer Scientific Inc., along with extensive regulatory, environmental, data privacy and healthcare policy risks.
Solventum Corporation reported fourth-quarter 2025 sales of $1.998 billion, down 3.7% on a reported basis but up 3.5% organically, showing underlying growth despite divestitures. GAAP diluted EPS rose to $0.36, while adjusted diluted EPS increased to $1.57.
For full-year 2025, sales reached $8.325 billion, up 0.9% with 3.3% organic growth. GAAP diluted EPS jumped to $8.88, largely reflecting a $1.549 billion gain on a business sale, while adjusted diluted EPS declined to $6.11 from $6.70. Operating cash flow fell to $369 million and free cash flow was slightly negative at $10 million. Long-term debt decreased to $5.035 billion from $7.810 billion. For 2026, Solventum guides to 2.0%–3.0% organic sales growth (3.0%–4.0% excluding SKU exits), adjusted EPS of $6.40–$6.60, and free cash flow of about $200 million.